WO2003093292A1 - 17α-FLUORALKYL-11β-BENZALDOXIM-STEROIDE, VERFAHREN ZU DEREN HERSTELLUNG, DIESE STEROIDE ENTHALTENDE PHARMAZEUTISCHE PRÄPARATE SOWIE DEREN VERWENDUNG ZUR HERSTELLUNG VON ARZNEIMITTELN - Google Patents

17α-FLUORALKYL-11β-BENZALDOXIM-STEROIDE, VERFAHREN ZU DEREN HERSTELLUNG, DIESE STEROIDE ENTHALTENDE PHARMAZEUTISCHE PRÄPARATE SOWIE DEREN VERWENDUNG ZUR HERSTELLUNG VON ARZNEIMITTELN Download PDF

Info

Publication number
WO2003093292A1
WO2003093292A1 PCT/EP2003/004686 EP0304686W WO03093292A1 WO 2003093292 A1 WO2003093292 A1 WO 2003093292A1 EP 0304686 W EP0304686 W EP 0304686W WO 03093292 A1 WO03093292 A1 WO 03093292A1
Authority
WO
WIPO (PCT)
Prior art keywords
benzaldehyde
oxoestra
oxime
pentafluoroethyl
dien
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2003/004686
Other languages
German (de)
English (en)
French (fr)
Inventor
Sven Ring
Gerd Schubert
Ingo Tornus
Günter Kaufmann
Walter Elger
Birgitt Schneider
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10221034A external-priority patent/DE10221034A1/de
Application filed by Schering AG filed Critical Schering AG
Priority to JP2004501431A priority Critical patent/JP2005536463A/ja
Priority to AU2003227717A priority patent/AU2003227717A1/en
Priority to AT03725149T priority patent/ATE307823T1/de
Priority to DE50301507T priority patent/DE50301507D1/de
Priority to EP03725149A priority patent/EP1501859B1/de
Publication of WO2003093292A1 publication Critical patent/WO2003093292A1/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J75/00—Processes for the preparation of steroids in general
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Definitions

  • the present invention relates to novel 17 ⁇ -fluoroalkyl-11 ⁇ -benzaldoxime steroids, a process for their preparation, pharmaceutical preparations containing these active substances and their use for the production of medicaments, in particular for postmenopausal substitution therapy for gynecological diseases such as uterine fibroids or dysmenoreal complaints.
  • Anti-gestagenic steroids are already known from EP 0 057 115 A2. These can be 3-oxo-estra-4,9-dienes which are substituted in the 11-position.
  • DE 43 32 283 A1 and DE 43 32 284 A1 describe 11 ⁇ -benzaldoxime-3-oxo-estra-4,9-diene derivatives which, according to DE 43 32 283 A1, are in the 17ß position with hydroxy, alkoxy, acyloxy or aryloxy and can be substituted in the 17 ⁇ position with ⁇ -fluoroalkyl.
  • steroids with 17 ⁇ -fluoroalkyl chains are disclosed in DE 197 06 061 A1.
  • ZK 230211 11 ⁇ - (4-acetylphenyl) -17ß- hydroxy-17 ⁇ - (1, 1, 2,2,2-pentafluoroethyl) estra-4,9-dien-3-one: U.Fuhrmann; H.Hess-Stumpp, A.CIeve, G.Neef, W.Schwede, J. Hoffmann, K.-H. Fritzemeier and K. Chwalisz: J. Med. Chem., 2000, 43, 5010-5016), show an almost pure antagonistic activity, high receptor selectivity and, inter alia, antiproliferative activity in tumor models.
  • the object on which the present invention is based is to find active compounds with an antigestagenic activity which have a significantly reduced antiglucocorticoid activity compared to the known compounds and which are suitable for postmenopausal substitution therapy or for the treatment of gynecological diseases such as uterine fibroids or dysmenoric complaints.
  • Another object on which the present invention is based is to find a process for the preparation of the active compounds.
  • Another task is to find pharmaceutical preparations that contain the active ingredients.
  • R. represents hydrogen, d- to C 6 -alkyl, COR ⁇ COOR 4) COSR 4 or CONHR 5 , in which R4 is C to C ⁇ -alkyl or unsubstituted or substituted aryl and in which R 5 is hydrogen, C to C ⁇ -alkyl or is unsubstituted or substituted aryl,
  • R 2 represents hydrogen, Cr to C 6 alkyl or C to C 6 acyl
  • any other substituents in particular alkyl and aryl groups, can be bonded instead of hydrogen.
  • the present invention also relates to pharmaceutically acceptable salts of these compounds.
  • Such acid addition salts can be salts of inorganic and organic acids, for example salts of hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, oxalic acid, maleic acid, fumaric acid, lactic acid, tartaric acid, malic acid, citric acid, salicylic acid, adipic acid and benzoic acid.
  • Other acids that can be used are described, for example, in: Progress in Pharmaceutical Research, vol.
  • the R ⁇ radicals mentioned in the present invention are in particular a hydrogen atom or a methyl group or acyl groups, such as, for example, formyl, acetyl, propionyl and benzoyl radicals, or carbonic acid ester groups, for example methoxycarbonyl or eth - Oxycarbonyl residues, or carbonic acid thiol ester groups, such as methylthiocarbonyl or ethylthiocarbonyl residues, or urethane groups, such as ethylaminocarbonyl or unsubstituted or substituted phenylaminocarbonyl residues.
  • the substituted phenylaminocarbonyl radical is preferably substituted with ad- to Ce-perfluoroalkyl radical.
  • R2 preferably represents a hydrogen atom, a methyl or an acetyl group.
  • R 3 can be 1, 1, 1-trifluoromethyl, 1, 1, 2,2,2-pentafluoroethyl or 1, 1, 2,2,3 , 3,3-heptafluoropropyl are available.
  • the compounds according to the invention are in particular the following 17 ⁇ -fluoroalkyl-11 ⁇ -benzaldoxime steroids:
  • the compounds according to the invention are suitable for postmenopausal substitution therapy, also in combination with an estrogen, or can be used for the treatment of gynecological diseases such as uterine fibroids or dysmenoric complaints.
  • the present invention also relates to a production process for the 17 ⁇ -fluoroalkyl-11 ⁇ -benzaldoxime steroids according to the invention.
  • the 17 ⁇ -fluoroalkyl groups can be introduced into the steroid skeleton by starting from a 17-ketone according to methods known per se.
  • Ruppert has described the production of trifluoromethyltrimethylsilane (Tetrahedron Letters, 1984, 25, 2195), which in the presence of tetrabutylammonium fluoride is ideally suited for introducing the trifluoromethyl group from aldehydes and ketones.
  • R. Krishnamurti, DR Bellew, GKS Prakash, J. Org. Chem., 1991, 56, 984 and Lamberth, J. Prakt. Chem., 1996, 338, 586-587, Ruppert 's Reagent R. Krishnamurti, DR Bellew, GKS Prakash, J. Org. Chem., 1991, 56, 984 and Lamberth, J. Prakt. Chem., 1996, 338, 586-587, Ruppert 's Reagent).
  • 17-ketones can be assumed for the introduction of the homologous fluoroalkyl groups into the steroid structure.
  • processes have been described in which fluoroalkyl compounds with the general formula halogen-C n F 2n + ⁇ are reacted with metals to form organometallic compounds of the alkali or alkaline earth series with the general formula metal-C n F 2 n + ⁇ in situ. Latter can then be reacted with the 17-ketones to give 17 ⁇ -fluoroalkyl-17 ⁇ -hydroxy compounds. (DE 197 06 061 A1).
  • the 17 ⁇ -fluoroalkoxymethyl grouping can preferably be introduced by a ring-opening reaction from a corresponding 17 (20) -spiroepoxide [Ponsold, Hübner, Schnabel, Stretch, Arzneistoff-Forschung (Drug Res.), 24 (1974) 896-900].
  • R 3 , R 4 , R 6 , R 7 and R 8 have the meaning of the formula II in EP 0 411 733 A2 corresponding radicals R 3 , R 4 ' , R 6 , R 7 and R 8 have:
  • the compound of the general formula II obtained by introducing the fluorinated alkyl group in the 17 ⁇ position with a salt of a hydroxylamine in a basic solvent, so that a 17 ⁇ -fluoroalkyl-11 ⁇ -benzaldoxime steroid is formed, in which R 1 is hydrogen, and then, if appropriate, to esterify, etherify or convert this compound into a corresponding carbamate, carbonic acid or thiocarbonic acid derivative.
  • R 1 is hydrogen
  • R 2 and R 3 in this general formula have the meanings given above.
  • the salt of the hydroxylamine is preferably a hydrochloride or hydrosulfate.
  • the basic solvent is preferably pyridine.
  • the compound having the general formula II can, in an alternative embodiment of the invention, also be reacted with a compound having the general formula NH 2 -O-R 1 , in which R 1 has the abovementioned meaning.
  • R 1 has the abovementioned meaning.
  • the 17 ⁇ -fluoroalkyl-11 ⁇ -benzaldoxime steroids according to the invention are bound to the progesterone receptor (cf. Tab. 1) and, compared to RU 486, have (11ß- (4-dimethylaminophenyl) -17ß-hydroxy-17 ⁇ -propinyl-estra-4 , 9-dien-3-one) usually has a significantly reduced antiglucocorticoid effect, demonstrated by the reduced glucocorticoid receptor binding in vitro (see Table 1).
  • N number of mated females
  • N # number of non-gravid females
  • the compounds according to the invention are suitable for postmenopausal substitution therapy and for the treatment of gynecological diseases, such as uterine fibroids, and for the treatment of dysmenoric complaints.
  • the present invention also relates to medicinal substances (pharmaceutical preparations) for oral, rectal, subcutaneous, intravenous or intramuscular use, which together with conventional carriers and optionally diluents contain at least one compound having the general formula I as active ingredient.
  • Medicaments according to the invention are produced with the customary solid or liquid carriers and / or diluents and the customarily generally used auxiliaries in accordance with the desired type of application in a suitable dosage and in a manner known per se.
  • tablets, film-coated tablets, dragees, capsules, pills, powders, solutions or suspensions are preferably also prepared as a depot form.
  • parenteral dosage forms such as injection solutions or suppositories should be considered.
  • Pharmaceutical forms as tablets can be prepared, for example, by mixing the active ingredient with known auxiliaries, such as dextrose, sugar, sorbitol, mannitol, polyvinylpyrrolidone, disintegrants, such as corn starch or alginic acid, binders, such as starch or gelatin, lubricants, such as magnesium stearate or talc, and / or Agents that can achieve a depot effect, such as carboxypolymethylene, carboxymethyl cellulose, cellulose acetate phthalate or polyvinyl acetate, can be obtained.
  • the tablets can also consist of several layers.
  • Coated tablets can be prepared analogously by coating cores produced analogously to the tablets with agents commonly used in tablet coatings, for example polyvinylpyrrolidone or shellac, gum arabic, talc, titanium dioxide or sugar.
  • the coated tablet case can also be made from consist of several layers, for example using the above-mentioned auxiliaries.
  • the solutions or suspensions with the active ingredient according to the invention can be mixed with substances such as saccharin, cyclamate or sugar, and / or with flavorings such as vanillin or orange extract. Furthermore, they can be mixed with suspending aids, such as sodium carboxymethyl cellulose or preservatives, such as p-hydroxybenzoic acid.
  • the capsules can be made by mixing the drug with carriers such as milk sugar or sorbitol, which are then placed in the capsules.
  • Suppositories can preferably be produced by mixing the active ingredient with suitable carrier materials, such as neutral fats or polyethylene glycols or their derivatives.
  • the galenical preparation contains the active substances in an amount of 1 to 100 mg, amounts in the range of 1,600 mg per day being required when used on humans.
  • This compound is prepared from 4- [17 ⁇ -methoxy-17 ⁇ - (1,1,2,2,2-pentafluoroethyl) -3-oxoestra-4,9-dien-11 ⁇ -yl] benzaldehyde according to the procedure according to Example 2 made with hydroxylamine hydrochloride in pyridine.
  • This compound is prepared according to Example 3 from 4- [17 ⁇ -methoxy-17 ⁇ - (1, 1, 2,2,2-pentafluoroethyl) -3-oxoestra-4,9-dien-11 ⁇ -yl] benzaldehyde- (1 U ) -oxime with 4-trifluoromethoxymethylphenyl isocyanate in toluene.
  • reaction solution is decomposed by adding 10 ml of 1N HCl. Allow to come to room temperature, stir for 2 hours, cool again to 0 ° C and add another 0.5 ml of 1,1,2,2,3,3,3-heptafluoropropyltrimethylsilane. After 15 minutes the solution is hydrolyzed by adding 15 ml of 1N HCl. After a further 30 minutes, 100 ml of saturated ammonium chloride solution are added and the solution is extracted with ethyl acetate. The organic phase is washed neutral, dried over sodium sulfate, the organic phase is filtered off and concentrated under vacuum.
  • the title compound is obtained from 4- [17 ⁇ -hydroxy-17 ⁇ - (1, 1, 2,2,3,3,3-heptafluoropropyl) -3-oxoestra-4,9-dien-11ß-yl] benzaldehyde by reaction prepared with hydroxylamine hydrochloride in pyridine according to Example 2.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PCT/EP2003/004686 2002-05-03 2003-05-05 17α-FLUORALKYL-11β-BENZALDOXIM-STEROIDE, VERFAHREN ZU DEREN HERSTELLUNG, DIESE STEROIDE ENTHALTENDE PHARMAZEUTISCHE PRÄPARATE SOWIE DEREN VERWENDUNG ZUR HERSTELLUNG VON ARZNEIMITTELN Ceased WO2003093292A1 (de)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2004501431A JP2005536463A (ja) 2002-05-03 2003-05-05 17α−フルオロアルキル−11β−ベンズアルドキシムステロイド、それらの製造方法、これらのステロイド類を含有する製剤及び医薬品製造のためのそれらの使用
AU2003227717A AU2003227717A1 (en) 2002-05-03 2003-05-05 17Alpha-FLUOROALKYL-11Beta-BENZALDOXIME-STEROIDS, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS CONTAINING SAID STEROIDS AND THE USE THEREOF IN THE PRODUCTION OF MEDICAMENTS
AT03725149T ATE307823T1 (de) 2002-05-03 2003-05-05 17a-fluoralkyl-11beta-benzaldoxim-steroide, verfahren zu deren herstellung, diese steroide enthaltende pharmazeutische präparate sowie deren verwendung zur herstellung von arzneimitteln
DE50301507T DE50301507D1 (de) 2002-05-03 2003-05-05 17a-FLUORALKYL-11BETA-BENZALDOXIM-STEROIDE, VERFAHREN ZU DEREN HERSTELLUNG, DIESE STEROIDE ENTHALTENDE PHARMAZEUTISCHE PRÄPARATE SOWIE DEREN VERWENDUNG ZUR HERSTELLUNG VON ARZNEIMITTELN
EP03725149A EP1501859B1 (de) 2002-05-03 2003-05-05 17a-FLUORALKYL-11BETA-BENZALDOXIM-STEROIDE, VERFAHREN ZU DEREN HERSTELLUNG, DIESE STEROIDE ENTHALTENDE PHARMAZEUTISCHE PRÄPARATE SOWIE DEREN VERWENDUNG ZUR HERSTELLUNG VON ARZNEIMITTELN

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10221034.9 2002-05-03
DE10221034A DE10221034A1 (de) 2002-05-03 2002-05-03 17alpha-Fluoralkyl-11ß-benzaldoxim-Steroide, Verfahren zu deren Herstellung, diese Steroide enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
US44940103P 2003-02-25 2003-02-25
US60/449,401 2003-02-25

Publications (1)

Publication Number Publication Date
WO2003093292A1 true WO2003093292A1 (de) 2003-11-13

Family

ID=29403591

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/004686 Ceased WO2003093292A1 (de) 2002-05-03 2003-05-05 17α-FLUORALKYL-11β-BENZALDOXIM-STEROIDE, VERFAHREN ZU DEREN HERSTELLUNG, DIESE STEROIDE ENTHALTENDE PHARMAZEUTISCHE PRÄPARATE SOWIE DEREN VERWENDUNG ZUR HERSTELLUNG VON ARZNEIMITTELN

Country Status (8)

Country Link
EP (1) EP1501859B1 (cg-RX-API-DMAC7.html)
JP (1) JP2005536463A (cg-RX-API-DMAC7.html)
AT (1) ATE307823T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003227717A1 (cg-RX-API-DMAC7.html)
DE (1) DE50301507D1 (cg-RX-API-DMAC7.html)
DK (1) DK1501859T3 (cg-RX-API-DMAC7.html)
ES (1) ES2252670T3 (cg-RX-API-DMAC7.html)
WO (1) WO2003093292A1 (cg-RX-API-DMAC7.html)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011009532A2 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-derivate, verfahren zu deren herstellung und deren verwendung zur behandlung von krankheiten
US8053426B2 (en) 2006-11-15 2011-11-08 Bayer Schering Pharma Ag Progesterone receptor antagonists
US8278469B2 (en) 2009-07-20 2012-10-02 Bayer Pharma Aktiengesellschaft 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives, method of production thereof and use thereof for the treatment of diseases
WO2013016725A1 (en) * 2011-07-28 2013-01-31 Evestra, Inc. Progesterone antagonists
US9085603B2 (en) 2010-02-10 2015-07-21 Bayer Intellectual Property Gmbh Progesterone receptor antagonists
US9096639B2 (en) 2009-07-20 2015-08-04 Bayer Intellectual Property Gmbh 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylene phenyl derivatives, methods for the production thereof and use thereof for treating diseases
US9096640B2 (en) 2009-07-20 2015-08-04 Bayer Intellectual Property 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-diene-11-methylene oxyalkylene aryl derivatives, process for preparation thereof, and use thereof for treatment of diseases
US9109004B2 (en) 2010-02-10 2015-08-18 Bayer Intellectual Property Gmbh Progesterone receptor antagonists
US9206219B2 (en) 2009-07-21 2015-12-08 Bayer Intellectual Property Gmbh 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl derivatives, methods for the production thereof and the use thereof for treating diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19706061A1 (de) * 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
EP0909764A1 (de) * 1997-10-11 1999-04-21 JENAPHARM GmbH 11 Beta-Benzaldoxim-9 Alpha, 10 Alpha-epoxy-estr-4-en-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Präparate

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19706061A1 (de) * 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
EP0909764A1 (de) * 1997-10-11 1999-04-21 JENAPHARM GmbH 11 Beta-Benzaldoxim-9 Alpha, 10 Alpha-epoxy-estr-4-en-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Präparate

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8053426B2 (en) 2006-11-15 2011-11-08 Bayer Schering Pharma Ag Progesterone receptor antagonists
US9156877B2 (en) 2009-07-20 2015-10-13 Bayer Intellectual Property Gmbh 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzylidene derivatives, methods for the production thereof and use thereof for treating diseases
WO2011009532A3 (de) * 2009-07-20 2011-04-21 Bayer Schering Pharma Aktiengesellschaft 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-derivate, verfahren zu deren herstellung und deren verwendung zur behandlung von krankheiten
US8278469B2 (en) 2009-07-20 2012-10-02 Bayer Pharma Aktiengesellschaft 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives, method of production thereof and use thereof for the treatment of diseases
US10155004B2 (en) 2009-07-20 2018-12-18 Bayer Intellectual Property Gmbh 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives, method of production thereof and use thereof for the treatment of diseases
WO2011009532A2 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-derivate, verfahren zu deren herstellung und deren verwendung zur behandlung von krankheiten
US9096639B2 (en) 2009-07-20 2015-08-04 Bayer Intellectual Property Gmbh 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylene phenyl derivatives, methods for the production thereof and use thereof for treating diseases
US9096640B2 (en) 2009-07-20 2015-08-04 Bayer Intellectual Property 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-diene-11-methylene oxyalkylene aryl derivatives, process for preparation thereof, and use thereof for treatment of diseases
US9206219B2 (en) 2009-07-21 2015-12-08 Bayer Intellectual Property Gmbh 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl derivatives, methods for the production thereof and the use thereof for treating diseases
US9085603B2 (en) 2010-02-10 2015-07-21 Bayer Intellectual Property Gmbh Progesterone receptor antagonists
US9109004B2 (en) 2010-02-10 2015-08-18 Bayer Intellectual Property Gmbh Progesterone receptor antagonists
CN103842370A (zh) * 2011-07-28 2014-06-04 伊万斯彻有限公司 黄体酮拮抗剂
WO2013016725A1 (en) * 2011-07-28 2013-01-31 Evestra, Inc. Progesterone antagonists

Also Published As

Publication number Publication date
DK1501859T3 (da) 2006-03-06
JP2005536463A (ja) 2005-12-02
EP1501859A1 (de) 2005-02-02
AU2003227717A1 (en) 2003-11-17
EP1501859B1 (de) 2005-10-26
DE50301507D1 (de) 2005-12-01
ATE307823T1 (de) 2005-11-15
ES2252670T3 (es) 2006-05-16

Similar Documents

Publication Publication Date Title
EP0648778B1 (de) Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
EP0254670B1 (de) 11beta-(4-Isopropenylphenyl)-estra-4,9-diene, deren Herstellung und diese enthaltende pharmazeutische Präparate
EP0299913B1 (de) 11Beta-Phenyl-4,9,15-Estratriene, deren Herstellung und diese enthaltende pharmazeutische Präparate
DE10221034A1 (de) 17alpha-Fluoralkyl-11ß-benzaldoxim-Steroide, Verfahren zu deren Herstellung, diese Steroide enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
EP1501859B1 (de) 17a-FLUORALKYL-11BETA-BENZALDOXIM-STEROIDE, VERFAHREN ZU DEREN HERSTELLUNG, DIESE STEROIDE ENTHALTENDE PHARMAZEUTISCHE PRÄPARATE SOWIE DEREN VERWENDUNG ZUR HERSTELLUNG VON ARZNEIMITTELN
EP1124841A1 (de) Gallensauer substituierte phenyl-alkenoylguanidine, verfahren zu ihrer herstellung, ihre verwendung als medikamente oder diagnostika sowie sie enthaltendes medika
EP1060187A1 (de) S-substituierte 11beta-benzaldoxim-estra-4,9-dien-kohlensäurethiolester, verfahren zu deren herstellung und diese verbindungen enthaltene pharmazeutische zubereitungen
DE1493150A1 (de) Verfahren zur Herstellung von tertiaeren Aminoalkyloximinoderivaten der OE?reihe
CH651053A5 (de) Steroid-zwischenprodukte.
EP0909764A1 (de) 11 Beta-Benzaldoxim-9 Alpha, 10 Alpha-epoxy-estr-4-en-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Präparate
WO1992011279A1 (de) D-HOMO-(16-EN)-11β-ARYL-4-ESTRENE, VERFAHREN ZU IHRER HERSTELLUNG SOWIE DEREN VERWENDUNG ALS ARZNEIMITTEL
WO1996008505A1 (de) Steroidester und -amide, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
DE2759994C2 (de) Ketale von 4-(1-Hydroxy-1-methylethyl)-3-cyclohexen-1-on und Verfahren zu ihrer Herstellung
EP1237903A1 (de) 11-beta-phenylestradien-derivate mit fluoralkylgruppen in der aromatischen seitenkette, deren herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen
EP1090028B1 (de) Ungesättigte 14,15-cyclopropano-androstane, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische präparate
DE2246462C3 (de) 15 α , 16 α -Methylen-4-pregnene, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel
DD289539A5 (de) Verfahren zur herstellung von 11 beta-(4-acetylphenyl)-17alpha-alkoxy-methyl-estra-4,9-dien-3-onen
AT233184B (de) Verfahren zur Herstellung von 3-Oxo-Δ<1,4>-steroiden
DE1958533C3 (de) Verfahren zur Herstellung von 17 alpha-Propadienyl-Gruppen enthaltenden Steroiden
DE3438500C1 (de) Verfahren zur Herstellung 11ß-substituierter Δ↑9↑-19-Norsteroide
DE1668124C3 (de) 9 alpha-Unsubstitulerte 11 beta-ChIoM 9-norsteroide, Verfahren zu deren Herstellung sowie diese enthaltende pharmazeutische Zusammensetzungen
DD299068A5 (de) Verfahren zur herstellung von 11 beta-arylsubstituierten 17 beta-alkoxy-17 alpha -alkoxymethyl-estra-4,9-dien-3-onen
DE102004019406A1 (de) 17α-Fluorsteroide
EP1658306A1 (de) Delta 15 -d-homosteroide mit androgener wirkung
CH433278A (de) Verfahren zur Herstellung eines steroiden cyclischen Acetals

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003725149

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2004501431

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2003725149

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2003725149

Country of ref document: EP